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Reactive oxygen speciesI review here the evidence that complex II of the respiratory chain (RC) constitutes a general sensor for
apoptosis induction. This concept emerged from work on neurodegenerative diseases and from recent data
on metabolic alterations in cancer cells affecting the RC and in particular on mutations of complex II subunits.
It is also supported by experiments with many anticancer compounds that compared the apoptosis sensitiv-
ities of complex II-deﬁcient versus WT cells. These results are explained by the mechanistic understanding of
how complex II mediates the diverse range of apoptosis signals. This protein aggregate is speciﬁcally activat-
ed for apoptosis by pH change as a common and early feature of dying cells. This leads to the dissociation of
its SDHA and SDHB subunits from the remaining membrane-anchored subunits and the consequent block of
it enzymatic SQR activity, while its SDH activity, which is contained in the SDHA/SDHB subcomplex, remains
intact. The uncontrolled SDH activity then generates excessive amounts of reactive oxygen species for the
demise of the cell. Future studies on these mitochondrial processes will help reﬁne this model, unravel the
contribution of mutations in complex II subunits as the cause of degenerative neurological diseases and
tumorigenesis, and aid in discovering novel interference options. This article is part of a Special Issue entitled:
Respiratory complex II: Role in cellular physiology and disease.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
1.1. Complex II in healthy cells: structure and function
In order to understand the role of complex II during apoptosis it
is appropriate to ﬁrst revisit the composition and function of this
protein aggregate in normal cells. The mitochondrial respiratory
chain (mRC) consists of four multimeric protein complexes, all of
which are anchored to the inner mitochondrial membrane (IMM).
Together they catalyze the oxidation of reducing equivalents, mainly
NADH, using molecular oxygen (O2) as the terminal electron accep-
tor, which ﬁnally yields water (Fig. 1) [1]. The electron transfer within
the mRC is coupled at speciﬁc points to the extrusion of protons into
the mitochondrial intermembrane space. This fuels the ATP synthase
complex (also known as complex V) thereby generating ATP. The
coupling between mRC and ATP synthesis is called oxidative phos-
phorylation (OXPHOS). All mRC complexes (mRCC) are multimeric
protein aggregates that are composed of factors encoded by either
nuclear or mitochondrial DNA. Complex II (also known as Succinate
Dehydrogenase (SDH) or Succinate Coenzyme Q Reductase (SQR))
is made up of only four subunits (SDHA, SDHB, SDHC and SDHD)
and as such is the smallest mRCC. It is the only complex to be fullytory complex II: Role in cellular
rights reserved.encoded by nuclear DNA. Apart frommRCC I, complex II is the second
entry point of reducing equivalents into the mRC via FADH, which is
generated by the oxidation of succinate to fumarate as part of the
tricarboxylic acid ((TCA), also known as citric acid or Krebs) cycle.
The electrons provided by complex II to the mRC then reduce coen-
zyme Q (CoQ) to ubiquinol, which is further shufﬂed along the mRC
[1] (Fig. 1). Another particularity of complex II, and the exception
among mRCCs, is that it is the only complex that does not serve to
pump protons across the IMM [2]. From the crystal structure of
complex II it was deduced that two transmembrane proteins, SDHC
and SDHD, anchor the complex to the IMM [3,4]. Their trans-
membrane domains hold a redox group, a heme b, bound at the inter-
face between SDHC and SDHD whose role for the transfer of electrons
within complex II is so far unknown for mammals [5,6]. In eukaryotic
cells the SDHB subunit is associated with the membrane anchors
SDHC and SDHD and together with SDHA forms the hydrophilic
head of the protein aggregate that protrudes into the mitochondrial
matrix. SDHA and SDHB constitute the catalytic core of the complex
that on its own can oxidize succinate (which directly binds to
SDHA) to fumarate in the TCA cycle. Within the SDHA/B sub-
complex the electrons are transported to the FAD cofactor contained
in SDHA and ﬁnally to the three [Fe–S] clusters in SDHB [2,3]. To mon-
itor the enzymatic activity of this part of complex II the electrons can
be captured in vitro by artiﬁcial, exogenously added electron accep-
tors. The corresponding enzymatic activity of complex II is called
succinate dehydrogenase activity (SDH) [7]. At the SDHC/SDHD inter-
face two CoQ-binding sites have been found: QP (“p” for proximal to
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Fig. 1. Schematic representation of the mitochondrial respiratory chain complexes and the OXPHOS system. The four complexes of the respiratory chain and the ATP synthase and
the electron/proton movements along these complexes are depicted. RCC I and II are the two main entries of reducing equivalents into the RC. RCC I receives electrons from NADH
and transfers them via a ﬂavin mononucleotide (FMN) cofactor to iron–sulfur (Fe–S) clusters to eventually reduce ubiquinone (coenzymeQ, CoQ, Q) to ubiquinol, which is coupled
to the translocation of protons from the matrix into the intermembrane space (IMS). RCC II (succinate:ubiquinone oxidoreductase) also contributes to the ubiquinol pool via the
transfer of electrons from succinate, a tricarboxylic acid (TCA) cycle intermediate, to the complex II-embedded cofactor FAD (ﬂavin-adenin dinucleotide) and then to several
Fe–S clusters. The ubiquinol pool delivers its electrons to RCC III (ubiquinol:cytochrome c oxidoreductase) through two heme centers (cytochromes b and c1) and one Fe–S cluster.
This is likewise coupled to a translocation of protons across the IMM. Finally, RCC III delivers its electrons to cytochrome c (Cyt C), which transfers them to RCC IV (cytochrome c
oxidase). This terminal RCC possesses uses the energy generated by the electron transfer to translocate protons. The ﬁnal complex, ATP synthase (complex V), uses the protomotive
force to generate ATP. This coupling between RC and ATP synthesis is called oxidative phosphorylation (OXPHOS).
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CoQ reduction at the QP site, which has a high afﬁnity for CoQ [8], is
assumed to be a two-step process. A partially reduced semiquinone
is formed by the ﬁrst electron transferred. This semiquinone radical
appears to be stabilized for complete reduction by the second electron
that then produces ubiquinol [2,9]. This mechanism is thought to safe-
guard complex II against excessive electron leakage under normal
physiological conditions [2,9]. The entire electron transfer within RCCII,
from succinate at the catalytic site of SDHA to CoQ at the QP site at the
SDHC/D interface, constitutes the succinate CoQ oxidoreductase (SQR)
activity of RCC II, which can be measured, similar to the SDH activity,
with an appropriate enzymatic assay in vitro [7].
2. A general role of complex II in apoptosis
The concept that complex II contributes to apoptosis evolved only
relatively recently based on its role in Leigh syndrome, also known as
Subacute Necrotizing Encephalomyelopathy (SNEM), a neurodegen-
erative disease that affects the central nervous system and is associated
with neuronal cell death, which eventually leads to impaired motor
functions [10]. The connection was discovered through SDHA muta-
tions that were linked to this disease [11], an observation that was
later corroborated by various studies in neuronal cells showing the
pro-apoptotic effects of speciﬁc complex II inhibitors, in particular the
irreversible complex II inhibitor 3-nitropropionic acid (3-NP) and the
competitive inhibitor methylmalonate [12,13]. Both reagents target
the succinate-binding site in SDHA and both, as a consequence, inhibit
the SDH aswell as the downstreamSQR activity [7,14]. Themost recent,
andmost prominent, indication that complex II is involved in apoptosisregulation was made when the tumor-suppressor gene function of
the SDHD, SDHC and SDHB subunits were discovered [15–17] (see
below). Three mechanisms were proposed to account for these results:
Firstly, the accumulation of succinate inmitochondria as a consequence
of complex II inhibition and its subsequent transport to the cytosol
where it inhibits HIF1α prolyl hydroxylase (PHD), leads to HIF1 stabili-
zation and the establishes a pseudo-hypoxic state. This favours glycoly-
sis and promotes tumor formation possibly through theWarburg effect
and its growth-promoting consequences, among them, notably, apo-
ptosis inhibition [18–20].
A second possible scenario of complex II inhibition, whose connec-
tion to apoptosis might be indirect, is that sublethal levels of superox-
ides are formed, which can contribute to either genomic instability
or tumorigenesis. In fact, it has been acknowledged for some time
that modest oxidative stress is furthering the proliferation of cells
[21–25]. The third explanation of the defects of complex II subunits
in cancer cells assumes a direct role of this protein aggregate in apo-
ptosis, i.e. that it acts as a sensor for cell death. If this sensor is not
properly functioning anymore, resistance to apoptosis signals builds
up that otherwise curtail tumor formation. Indeed, various studies
brought to light the role of complex II as a pro-apoptotic sensor. The
ﬁrst study suggesting than complex II is a transmitter of apoptosis
signals observed that after mitochondrial outer membrane (MOM)
permeabilization, a crucial step in apoptosis signalling, complex II
(and complex I) are inhibited in a caspase-dependent manner and
contribute to apoptotic cell death via reactive oxygen species (ROS)
production and ΔΨμ collapse [26]. ROS formation is a common
theme when complexes of the RC are integrated into the apoptosis
signalling process. This is achieved through the production of high,
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contribute to tumor formation – and is caused by the abrupt bock of
the electron ﬂow within the mRC. How exactly ROS are produced at
complex II has not fully been resolved, mostly due to the fact that
complexes I and III were so far predominantly investigated as princi-
pal sources of mitochondrial ROS [1,27,28]. In the few studies that
looked at ROS formation by complex II, different sites for superoxide
production were identiﬁed, depending on the respective chemical
inhibitors used or the speciﬁc sequence of the mutations analyzed.
The CoQ-binding site formed by SDHB/C/D [29] was proposed,
possibly through the stabilization of the semiquinone radical [30];
alternatively the FAD in SDHA was identiﬁed [4]; and ﬁnally a so far
undeﬁned site between the SDHA-embedded FAD and a downstream
blockade was singled out [7,22]. After the initial implication of com-
plex II in apoptosis signalling [26], a later study showed that apopto-
sis induced by nerve growth factor (NGF) withdrawal depends on a
functional complex II in neurons [31]. This observation was subse-
quently extended by demonstrating that NGF deprivation activates
the transcription factor c-Jun and apoptosis via PHD3 (EglN3), a
prolyl hydroxylase involved in HIF1α degradation. In this case,
however, the apoptosis induction appeared to be independent of
HIF1α and instead relied on KIF1Bβ, a motor protein implicated in
anterograde transport of synaptic vesicles whose connection to apo-
ptosis induction remains unknown [32]. Taken together, these data
strongly suggested that the protein aggregate of complex II acts as a
sensor for apoptosis induction.
3. Complex II as a pH sensor for apoptosis
A recent series of experiments not only broadened the scope of apo-
ptosis signals mediated through complex II but also led to amechanistic
understanding how this complex is activated for apoptosis induction. A
genetic high-throughput screen led to the isolation of various apoptosis
genes, among them SDHC and SDHD (but not SDHAnor SDHB) [33–39].
Overexpression of SDHC caused robust apoptosis and cells deﬁcient of
its protein and therefore lacking an intact complex II were signiﬁcantly
more resistant to numerous structurally diverse anticancer drugs, rang-
ing from cisplatin, etoposide, doxorubicin, to paclitaxel and also to
proapoptotic cytokines [5,40,33]. Based on the efﬁciency and swiftness
of the pro-effect of SDHC, a direct effect, possibly on the assembly of
complex II is likely, rather than an indirect such as compromising the
mitochondrial import [41]. Importantly, all agents, including SDHC
expression, inhibited the activity of complex II even before overt signs
of cell death were observable implying that it is an early cellular
response [33]. While this cell death was shown to be dependent on
ROS formation, the exact mechanism of their formation remained
unresolved [33]. This was addressed in a follow-up study, which
revealed that all those divers apoptosis agents listed above speciﬁcally
reduced the SQR of complex II without impairing its SDH activity [7]. In
agreement with this, the complex II inhibitors thenoyltriﬂuoroacetate
(TTFA), α-tocopheryl succinate (α-TOS), and Aptenins, which target
the SQR activity throughbinding the proximalQP site [3], likewise caused
apoptosis [7,42,43]. The speciﬁc SDH inhibitor 3-nitroproprionic acid
(3-NP) and succinate competitors (malonate derivatives), on the other
hand, did not only not lead to the demise of the cells but actually rescued
them. This is also supported by mutants of the complex II subunits such
as the mev-1 mutant of SDHC in the CoQ-binding site, which features
mitochondrial superoxide production and apoptosis through the speciﬁc
inhibition of the SQR activity without SDH function impairment
[44]. Other mutations in SDHB/C/D at the CoQ-binding site have been
shown to replicate these effects [24,29,45,46]. This suggested that it is
crucial exactly how complex II is inhibited for apoptosis induction:
when SQR activity is blocked while the enzymatic SDH activity is still
intact. The ensuing massive leakage of electrons from complex II to
molecular oxygen can then generate enough superoxides for apoptosis
induction [7]. When the integrity of complex II during apoptosis wasinvestigated with blue native gels, it was observed that apoptosis induc-
tion is correlated with the speciﬁc disintegration of complex II by the
release of SDHA and SDHB from the membrane-anchoring subunits
into the matrix. As the SDHA/SDHB sub-complex is still enzymatically
active [47,48], it can efﬁciently remove electrons from its substrate succi-
nate. However, since the physiological downstream acceptors for the
electrons (the SDHC/D subunits) aremissing, the electronﬂow is blocked
and the electrons are transferred to molecular oxygen instead. This
uncontrolled enzymatic activity thereby generates excessive ROS and
causes apoptosis induction [7,33]. This, however, is not the only way in
which complex II can, even though much less efﬁciently, generate ROS.
Wehave observed that over a long incubation period 3-NP also generates
oxidative stress and leads to cell death, albeit inefﬁciently (unpublished).
This is probably the scenario that is relevant for the neurodegenerative
Leigh syndrome with mutations in SDHA (above). The ﬁndings on com-
plex II disintegration seamlessly integrate the data on the differential
inhibition of the two enzymatic activities of complex II (SDH and SQR)
observed with chemicals (above) and led to a mechanistic understand-
ing of how complex II is activated for apoptosis induction.
The second most pressing question emerging from the studies on
complex II inhibition was how so many structurally diverse signals
can converge on one protein complex. What, in other words, is the
common denominator that combines all those agents that signal
through complex II? We found evidence that the speciﬁc disintegra-
tion of complex II was accomplished through intracellular acidiﬁca-
tion, which occurs both in the cytosol and the mitochondria as an
early and universal change during the apoptotic process [49]. This
seems – perhaps through the protonation of amino acid side chains
in complex II subunits – to impact on the interactions within complex
II and drives the release of the catalytic SDHA/SDHB subunits from the
membrane-anchoring subunits of complex II [7]. When isolated
mitochondria were incubated in buffers with different pH, a reduc-
tion from pH 7.3 to 6.7 caused a release of SDHA/B, which was also
observed in mitochondria isolated from cells undergoing apoptosis.
Conversely, the transfection of the sodium/hydrogen exchanger
NHE1, which maintains the physiological pH, also inhibited the disin-
tegration of complex II. However, how direct or indirect the effect of
the pH drop during apoptosis on the release of complex II subunits
is, remains unknown. Also, the pH sensor function of RCC II is certainly
not the only mediator of apoptosis activated by acidiﬁcation. Caspases,
endonucleases and proapoptotic Bcl2 family members have also been
shown to be activated by the apoptotic pH drop, though it could be
argued that they are part of the execution machinery of cell death and
hence act at a later point in apoptosis signaling [49]. In other scenarios
of physiological pH decline, e.g. metabolic acidosis or lactic acidosis,
which are not associated with cell death, the oxidative stress caused
by complex II inhibition must be overcome but how this is accom-
plished remains to be determined.
ROS are formed as a consequence of the disintegration of complex II.
These molecules then act in a pleiotropic way in the cell for apoptosis
induction; they crosslink proteins, produce ceramide, oxidize GSH and
proteins in the mitochondrial permeability transition (PT) pore, activate
JNK, and damageDNA [50]. As various RCCs are directly impacted by ROS
as revealed in isolated mitochondria and in intact cells ROS can also act
on the RCCs by establishing a feed-forward loop of RC inhibition, ROS
formation and further inhibition of the RCCs [51–53]. This can be accom-
plished by posttranslationalmodiﬁcations of the subunits by lipid perox-
idation adducts (4-hydroxynonenal, HNE, or malondialdehyde MDA),
carbonylation or nitration of residues and ﬁnally a block of their activities
[54–57]. Superoxides generated through ischemia/reperfusion prevent
the correct glutathionylation of SDHA in complex II, which facilitates its
nitration by peroxynitrite on tyrosine residues and diminishes its activity
[58,59]. Which one of those processes is the downstream apoptosis
executioner of complex II disintegration remains to be determined.
Hence, while the ﬁnding about the dissociation of complex II subunits
and the establishment of oxidative stress answer a number of questions,
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propose the model depicted in Fig. 2 in which apoptosis leads to an
early cellular pH drop causing the dissociation of complex II subunits
SDHA/B so that its SDH activity remains intact and its SQR activity is
curtailed. This produces the catalytic formation of ROS and ﬁnally cell
death induction though oxidative stress. Hence, complex II is a mito-
chondrial sensor for pH change as a widespread initiating event in apo-
ptotic cells [49]. It is therefore, apart from complex I of the RC whose
subunit NDUFS1 is cleaved by caspases [60], the second complex of theFADH2
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4. Mutations in tumors affecting apoptosis though complex II
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apoptosis signals determines both tumorigenesis and the clinical out-
come of cancer treatment. Based to the wide range of cell death signals
acting on malignant cells, many cellular mediators of apoptosis are
impaired in cancers. In this section of the review I will give an overview
of themRC alterations found in tumor cells, both general ones and those
speciﬁcally affecting complex II subunits and discuss how their occur-
rence can be explained by the new role of complex II as a general sensor
for apoptosis signals and by the mechanistic understanding of how it
causes apoptosis. I will ﬁrst turn cover general changes in tumor cells
that incapacitate complex II as an apoptosis sensor.
It is well known that cancer cells remodel their metabolism. As a
result, the activity of the respiratory chain is reduced while glycolysis
is increased (the so-called Warburg effect [63–65]). This is achieved
through a range of biochemical changes that also confer a growth
advantage to the malignant cells. Lactate, the end product of glycoly-
sis, for example, sustains tumor growth by changing the microenvi-
ronment of the tumor cells and also diminish OXPHOS. While this
might have a consequence for many other mediators of apoptosis,
including Bax and Bak [18], this should also affect complex II as a gen-
eral mediator of apoptosis signals. The electron ﬂow through RCC II is
disrupted during its activation for apoptosis and hence a reduced ﬂow
a priori should likewise reduce its apoptosis effect. Even though this
seems to be a plausible view, it should be stressed that this has not
formally been shown. Nevertheless, when the activity of the respira-
tory chain is reduced the cells' ability to form reactive oxygen species
is likewise decreased [66]. More deﬁnitive data exists on the bio-
chemical regulators of the Warburg effect and how they affect com-
plex II: the HIF1α transcription factor is activated during hypoxia
and enhances glycolysis by tilting the balance between pyruvate
dehydrogenase (PDH) and lactate dehydrogenase (LDH) in favour of
the latter [67–69], HIF1α targets the Bcl-2 family member BNIP3
[70] to establish a global RC inhibition [71], HIF1α's microRNA-210
target reduces RCC IV activity [72], and ﬁnally HIF1α even initiates
the direct downregulation of the expression of SDHB [73,74].
Apart from these global RC curtailments speciﬁc mutations are also
affecting complex II as it contains tumor suppressor proteins [15–17].
Germ-line loss-of-function mutations in SDHB, SDHD (also known as
cytochrome bS or cybS) and, albeit more rarely, SDHC (also known
as cytochrome bL or cybL) predispose carriers to paragangliomas.
Paragangliomas originate from neuronal cells in paraganglia from the
skull base to the pelvic ﬂoor of chromafﬁn-negative glomus cells
derived from the embryonic neural crest. These cells are part of the
sympathetic nervous system (a branch of the autonomic nervous sys-
tem) and normally act as special chemoreceptors located along blood
vessels, particularly in the carotid bodies and in aortic bodies. Complex
II mutations cause head and neck paragangliomas (PGL), extra-adrenal
PGL, and paragangliomas of the medulla of the adrenal gland known as
pheochromocytomas (PH). The neuro-endocrine tumors PGL and PH
are considered as relatively rare with a yearly incidence of 1–2 per
1,000,000, respectively [75]. These SDHB/C/D mutations account for
15% of all hereditary cases of those tumors [2] and, since they show
loss of heterozygosity by somatic mutation of the normal allele, they
constitute classical tumor suppressor genes [75]. Mutations of the
same subunits have also been found in 11-16% of patients with appar-
ently sporadic PGL [76,77] but appear to be absent in sporadic PH
[78,79]. Mutated SDHB in those tumors is regarded as a high-risk factor
for malignancy, poor prognosis and metastasis [80–82]. Complex II
mutations have also been found in other types of cancers. SDHB muta-
tions, for example, have been associated with renal cell carcinomas
[83,84] and neuroblastoma [85], and SDHB or SDHD mutations were
detected in papillary thyroid cancer [83]. Mutations in SDHB, SDHC,
and SDHD have also been detected in hereditary PGL-associated gastro-
intestinal stromal tumors (GIST) [86] and sporadic GIST [87]. While
numerous germ-line mutations were found in the iron–sulfur subunit
of complex II (Ip, SDHB) and in its two small membrane-anchoringsubunits SDHC and SDHD [88], only one mutation in SDHA leading to
PGL has been reported so far [89]. These mutations have in common
that the abundance of complex II in the IMM of carrier patients is
reduced: Mutations in SDHA [89], SDHB [90,91], SDHC [91], SDHD
[91–93] and SDHAF2 [94] all lead to the complete absence or at least a
dramatic decrease of complex II and its enzymatic activity, both in
PGL/PH tumors [91] and in GIST [87]. This is even found in the absence
of mutations in the coding sequence of complex II-subunits; individual
SDH genes can also be markedly downregulated in PGL/PH [78,95] and
in other types of cancers [96,97] suggesting that downregulation of RCC
proteins in tumors can have similar effects as mutations in the protein
sequence.
Hence, the inhibition of the RC is widespread in cancer and inti-
mately connected to apoptosis resistance. In both scenarios, when
complex II is downregulated as a consequence of the general shift
from OXPHOS to glycolysis and in the tumors with speciﬁc complex
II subunit mutations, the end result is a reduction of its activity and
consequently its ability to contribute to ROS production and apopto-
sis induction upon receiving pro-apoptotic signals, through which
the tumor cells become desensitized.
The model through which complex II induces apoptosis emphasises
its speciﬁc disintegration. Recently evidence emerged that the assembly
of complex II is regulated. This suggests, but does not prove, that its dis-
assembly is reversible. Two assembly factors for complex II were discov-
ered, one acting on SDHA ﬂavination (SDH5 or SDHAF2, [94]) and the
other putatively on SDHB (SDHAF1, [98]). A relatively rare mutation
of SDH5 was identiﬁed in PGL [94,99]. In line with a role in apoptosis,
Tcm62, another complex II assembly factor discovered in yeast [100]
and prohibitin (PHB), its putative mammalian homologue, have been
implicated in cell death inhibition following growth factor withdrawal
[101]. Both proteins act as mitochondrial chaperones and are required
for mitochondrial respiratory function [100,102–104]. This could indi-
cate that members of this chaperone family can re-assemble complex
II during apoptosis and thereby decrease ROS formation and cell
death. In interesting recent study implicated cardiolipin, amitochondrial
lipid that is predominantly contained in the IMM, as being required for
the assembly of complex II [105]. With the known role of cardiolipin
for apoptosis regulation [106] this ﬁndingmight represent an important
connection to diseases of cardiolipin deﬁciency such as the X-linked
cardioskeletal myopathy and neutropenia (Barth syndrome). This dis-
ease is caused by mutations in the tafazzin gene whose gene product
is believed to function as an acyltransferase in lipid metabolism and
cells from such patients displays reduced apoptosis [107].
It is interesting to note that attempts have been made, with
promising-looking results, to pharmaceutically target complex II for
apoptosis induction in tumor cells [43,108,109].
5. Known unknowns of complex II
While we have undoubtedly made progress in deciphering how
complex II contributes to the demise of the cell as a general apoptosis
sensor, a number of questions remain or even emerged from the new
insights. Is, for example, complex II mediating only accidental cell
death, i.e. when cells are stressed or is this complex also involved in
developmental cell death, i.e. intentional cell death? Another impor-
tant question concerns the exact molecular details of how complex
II can sense the pH change and disintegrate during apoptosis. The
assumption was made here that amino acid side chains are protonated
but it could also be dependent on amore indirect effect. Also, themodel
about the disintegration of complex II for apoptosis puts into focus a
long-ignored aspect of this protein aggregate: its assembly and poten-
tially its re-assembly. The chaperones mentioned here are prime candi-
date for the regulation of the integrity of the protein complex and, as a
consequence, of apoptosis induction. Moreover, the various mutations
that have been observed within complex II, both in tumors and
neurodegenerative diseases, have been explained in the context of the
570 S. Grimm / Biochimica et Biophysica Acta 1827 (2013) 565–572model of how complex II is activated for apoptosis. However, this has to
be rigorously tested in each case. In particular the consequences of a
reduced electron ﬂow on the disintegration of and ROS formation by
complex II have to be investigated. Last but not least the tissue speciﬁc-
ity of the complex II subunit mutations for certain tumors has to be
explained.
In conclusion, future studies on the role of complex II in apoptosis
will contribute to a better understanding of the degenerative and
proliferation diseases complex II is involved in and hopefully to novel
rational therapeutic interference.
Acknowledgements
I wish to acknowledge the ﬁnancial support from the Cancer
ResearchUKaswell as from theWellcomeTrust, CRUK,MRC, and Breast
Cancer Campaign.
References
[1] G. Lenaz, M.L. Genova, Structure and organization of mitochondrial respiratory
complexes: a new understanding of an old subject, Antioxid. Redox Signal. 12
(2010) 961–1008.
[2] J. Rutter, D.R. Winge, J.D. Schiffman, Succinate dehydrogenase — assembly,
regulation and role in human disease, Mitochondrion 10 (2010) 393–401.
[3] F. Sun, X. Huo, Y. Zhai, A. Wang, J. Xu, D. Su, M. Bartlam, Z. Rao, Crystal structure
of mitochondrial respiratory membrane protein complex II, Cell 121 (2005)
1043–1057.
[4] V. Yankovskaya, R. Horseﬁeld, S. Tornroth, C. Luna-Chavez, H. Miyoshi, C. Leger,
B. Byrne, G. Cecchini, S. Iwata, Architecture of succinate dehydrogenase and
reactive oxygen species generation, Science 299 (2003) 700–704.
[5] A. Lemarie, S. Grimm, Mutations in the heme b-binding residue of SDHC inhibit
assembly of respiratory chain complex II in mammalian cells, Mitochondrion 9
(2009) 254–260.
[6] K.S. Oyedotun, C.S. Sit, B.D. Lemire, The Saccharomyces cerevisiae succinate dehy-
drogenase does not require heme for ubiquinone reduction, Biochim. Biophys.
Acta 1767 (2007) 1436–1445 (Epub 2007 Sep 1429).
[7] A. Lemarie, L. Huc, E. Pazarentzos, A.L. Mahul-Mellier, S. Grimm, Speciﬁc disinte-
gration of complex II succinate:ubiquinone oxidoreductase links pH changes to
oxidative stress for apoptosis induction, Cell Death Differ. 18 (2011) 338–349.
[8] E. Maklashina, G. Cecchini, The quinone-binding and catalytic site of complex II,
Biochim. Biophys. Acta 1797 (2010) 1877–1882.
[9] J. Guo, B.D. Lemire, The ubiquinone-binding site of the Saccharomyces cerevisiae
succinate–ubiquinone oxidoreductase is a source of superoxide, J. Biol. Chem.
278 (2003) 47629–47635.
[10] J. Finsterer, Leigh and Leigh-like syndrome in children and adults, Pediatr.
Neurol. 39 (2008) 223–235.
[11] T. Bourgeron, P. Rustin, D. Chretien, M. Birch-Machin, M. Bourgeois, E.
Viegas-Pequignot, A. Munnich, A. Rotig, Mutation of a nuclear succinate
dehydrogenase gene results in mitochondrial respiratory chain deﬁciency, Nat.
Genet. 11 (1995) 144–149.
[12] B.A. McLaughlin, D. Nelson, I.A. Silver, M. Erecinska, M.F. Chesselet, Methylmalonate
toxicity in primary neuronal cultures, Neuroscience 86 (1998) 279–290.
[13] Z. Pang, J.W. Geddes, Mechanisms of cell death induced by the mitochondrial
toxin 3-nitropropionic acid: acute excitotoxic necrosis and delayed apoptosis,
J. Neurosci. 17 (1997) 3064–3073.
[14] A.M. Brusque, R. Borba Rosa, P.F. Schuck, K.B. Dalcin, C.A. Ribeiro, C.G. Silva, C.M.
Wannmacher, C.S. Dutra-Filho, A.T. Wyse, P. Briones, M. Wajner, Inhibition of
the mitochondrial respiratory chain complex activities in rat cerebral cortex
by methylmalonic acid, Neurochem. Int. 40 (2002) 593–601.
[15] B.E. Baysal, R.E. Ferrell, J.E. Willett-Brozick, E.C. Lawrence, D. Myssiorek, A. Bosch,
A. van der Mey, P.E. Taschner, W.S. Rubinstein, E.N. Myers, C.W.r. Richard, C.J.
Cornelisse, P. Devilee, B. Devlin, Mutations in SDHD, a mitochondrial complex
II gene, in hereditary paraganglioma, Science 287 (2000) 848–851.
[16] S. Niemann, U. Muller, Mutations in SDHC cause autosomal dominant
paraganglioma, type 3, Nat. Genet. 26 (2000) 268–270.
[17] D. Astuti, F. Latif, A. Dallol, P.L. Dahia, F. Douglas, E. George, F. Skoldberg, E.S.
Husebye, C. Eng, E.R. Maher, Gene mutations in the succinate dehydrogenase
subunit SDHB cause susceptibility to familial pheochromocytoma and to familial
paraganglioma, Am. J. Hum. Genet. 69 (2001) 49–54.
[18] A. Tomiyama, S. Serizawa, K. Tachibana, K. Sakurada, H. Samejima, Y. Kuchino, C.
Kitanaka, Critical role for mitochondrial oxidative phosphorylation in the
activation of tumor suppressors Bax and Bak, J. Natl. Cancer Inst. 98 (2006)
1462–1473.
[19] G. Kroemer, J. Pouyssegur, Tumor cell metabolism: cancer's Achilles' heel,
Cancer Cell 13 (2008) 472–482.
[20] V. Gogvadze, B. Zhivotovsky, S. Orrenius, The Warburg effect and mitochondrial
stability in cancer cells, Mol. Aspects Med. 31 (2010) 60–74.
[21] J.P. Fruehauf, F.L. Meyskens Jr., Reactive oxygen species: a breath of life or death?
Clin. Cancer Res. 13 (2007) 789–794.[22] R.D. Guzy, B. Sharma, E. Bell, N.S. Chandel, P.T. Schumacker, Loss of the SdhB, but
Not the SdhA, subunit of complex II triggers reactive oxygen species-dependent
hypoxia-inducible factor activation and tumorigenesis, Mol. Cell. Biol. 28 (2008)
718–731.
[23] T. Ishii, K. Yasuda, A. Akatsuka, O. Hino, P.S. Hartman, N. Ishii, A mutation in the
SDHC gene of complex II increases oxidative stress, resulting in apoptosis and
tumorigenesis, Cancer Res. 65 (2005) 203–209.
[24] N. Senoo-Matsuda, K. Yasuda, M. Tsuda, T. Ohkubo, S. Yoshimura, H. Nakazawa,
P.S. Hartman, N. Ishii, A defect in the cytochrome b large subunit in complex II
causes both superoxide anion overproduction and abnormal energy metabolism
in Caenorhabditis elegans, J. Biol. Chem. 276 (2001) 41553–41558.
[25] B.G. Slane, N. Aykin-Burns, B.J. Smith, A.L. Kalen, P.C. Goswami, F.E. Domann, D.R.
Spitz, Mutation of succinate dehydrogenase subunit C results in increased O2.-,
oxidative stress, and genomic instability, Cancer Res. 66 (2006) 7615–7620.
[26] J.E. Ricci, R.A. Gottlieb, D.R. Green, Caspase-mediated loss of mitochondrial
function and generation of reactive oxygen species during apoptosis, J. Cell
Biol. 160 (2003) 65–75 (Epub 2003 Jan 2006).
[27] H.R. McLennan, M. Degli Esposti, The contribution of mitochondrial respiratory
complexes to the production of reactive oxygen species, J. Bioenerg. Biomembr.
32 (2000) 153–162.
[28] J.E. Ricci, N. Waterhouse, D.R. Green, Mitochondrial functions during cell death, a
complex (I-V) dilemma, Cell Death Differ. 10 (2003) 488–492.
[29] S.S. Szeto, S.N. Reinke, B.D. Sykes, B.D. Lemire, Ubiquinone-binding site muta-
tions in the Saccharomyces cerevisiae succinate dehydrogenase generate super-
oxide and lead to the accumulation of succinate, J. Biol. Chem. 282 (2007)
27518–27526.
[30] Q.M. Tran, R.A. Rothery, E. Maklashina, G. Cecchini, J.H. Weiner, The quinone
binding site in Escherichia coli succinate dehydrogenase is required for electron
transfer to the heme b, J. Biol. Chem. 281 (2006) 32310–32317.
[31] S. Lee, E. Nakamura, H. Yang, W. Wei, M.S. Linggi, M.P. Sajan, R.V. Farese, R.S.
Freeman, B.D. Carter, W.G. Kaelin Jr., S. Schlisio, Neuronal apoptosis linked to
EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmen-
tal culling and cancer, Cancer Cell 8 (2005) 155–167.
[32] S. Schlisio, R.S. Kenchappa, L.C. Vredeveld, R.E. George, R. Stewart, H. Greulich, K.
Shahriari, N.V. Nguyen, P. Pigny, P.L. Dahia, S.L. Pomeroy, J.M. Maris, A.T. Look, M.
Meyerson, D.S. Peeper, B.D. Carter, W.G. Kaelin Jr., The kinesin KIF1Bbeta acts
downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor
suppressor, Genes Dev. 22 (2008) 884–893.
[33] T. Albayrak, V. Scherhammer, N. Schoenfeld, E. Braziulis, T. Mund, M.K. Bauer, I.E.
Schefﬂer, S. Grimm, The tumor suppressor cybL, a component of the respiratory
chain, mediates apoptosis induction, Mol. Biol. Cell 14 (2003) 3082–3096.
[34] S. Grimm, The art and design of genetic screens: mammalian culture cells, Nat.
Rev. Genet. 5 (2004) 179–189.
[35] S. Grimm, V. Kachel, Robotic high-throughput assay for isolating apoptosis-
inducing genes, Biotechniques 32 (2002) 670–677.
[36] V. Kachel, G. Sindelar, S. Grimm, High-throughput isolation of ultra-pure plasmid
DNA by a robotic system, BMC Biotechnol. 6 (2006) 9.
[37] T. Albayrak, S. Grimm, A high-throughput screen for single gene activities: isolation
of apoptosis inducers, Biochem. Biophys. Res. Commun. 304 (2003) 772–776.
[38] S. Grimm, P. Leder, An apoptosis-inducing isoform of neu differentiation factor
(NDF) identiﬁed using a novel screen for dominant, apoptosis-inducing genes,
J. Exp. Med. 185 (1997) 1137–1142.
[39] S. Grimm, E.J. Weinstein, I.M. Krane, P. Leder, Neu differentiation factor (NDF), a
dominant oncogene, causes apoptosis in vitro and in vivo, J. Exp. Med. 188
(1998) 1535–1539.
[40] F.G. Oostveen, H.C. Au, P.J. Meijer, I.E. Schefﬂer, A Chinese hamster mutant cell
line with a defect in the integral membrane protein CII-3 of complex II of the
mitochondrial electron transport chain, J. Biol. Chem. 270 (1995) 26104–26108.
[41] N. Gebert, M. Gebert, S. Oeljeklaus, K. von derMalsburg, D.A. Stroud, B. Kulawiak, C.
Wirth, R.P. Zahedi, P. Dolezal, S.Wiese, O. Simon, A. Schulze-Specking, K.N. Truscott,
A. Sickmann, P. Rehling, B. Guiard, C. Hunte, B. Warscheid, M. van der Laan, N.
Pfanner, N. Wiedemann, Dual function of Sdh3 in the respiratory chain and
TIM22 protein translocase of the mitochondrial inner membrane, Mol. Cell 44
(2011) 811–818.
[42] S. Krahenbuhl, M. Chang, E.P. Brass, C.L. Hoppel, Decreased activities of
ubiquinol:ferricytochrome c oxidoreductase (complex III) and ferrocytochrome
c:oxygen oxidoreductase (complex IV) in liver mitochondria from rats with
hydroxycobalamin[c-lactam]-induced methylmalonic aciduria, J. Biol. Chem.
266 (1991) 20998–21003.
[43] L.F. Dong, V.J. Jameson, D. Tilly, J. Cerny, E. Mahdavian, A. Marin-Hernandez, L.
Hernandez-Esquivel, S. Rodriguez-Enriquez, J. Stursa, P.K. Witting, B. Stantic, J.
Rohlena, J. Truksa, K. Kluckova, J.C. Dyason, M. Ledvina, B.A. Salvatore, R.
Moreno-Sanchez, M.J. Coster, S.J. Ralph, R.A. Smith, J. Neuzil, Mitochondrial
targeting of vitamin E succinate enhances its pro-apoptotic and anti-cancer
activity via mitochondrial complex II, J. Biol. Chem. 286 (2011) 3717–3728.
[44] N. Ishii, M. Fujii, P.S. Hartman, M. Tsuda, K. Yasuda, N. Senoo-Matsuda, S. Yanase,
D. Ayusawa, K. Suzuki, A mutation in succinate dehydrogenase cytochrome b
causes oxidative stress and ageing in nematodes, Nature 394 (1998) 694–697.
[45] Z. Zhao, R.A. Rothery, J.H. Weiner, Effects of site-directed mutations in
Escherichia coli succinate dehydrogenase on the enzyme activity and production
of superoxide radicals, Biochem. Cell Biol. 84 (2006) 1013–1021.
[46] J. Huang, B.D. Lemire, Mutations in the C. elegans succinate dehydrogenase iron–
sulfur subunit promote superoxide generation and premature aging, J. Mol. Biol.
387 (2009) 559–569.
[47] G. Cecchini, Function and structure of complex II of the respiratory chain, Annu.
Rev. Biochem. 72 (2003) 77–109.
571S. Grimm / Biochimica et Biophysica Acta 1827 (2013) 565–572[48] K. Nakamura, M. Yamaki, M. Sarada, S. Nakayama, C.R. Vibat, R.B. Gennis, T.
Nakayashiki, H. Inokuchi, S. Kojima, K. Kita, Two hydrophobic subunits are
essential for the heme b ligation and functional assembly of complex II (succinate–
ubiquinone oxidoreductase) from Escherichia coli, J. Biol. Chem. 271 (1996) 521–527.
[49] D. Lagadic-Gossmann, L. Huc, V. Lecureur, Alterations of intracellular pH homeo-
stasis in apoptosis: origins and roles, Cell Death Differ. 11 (2004) 953–961.
[50] M.L. Circu, T.Y. Aw, Reactive oxygen species, cellular redox systems, and apoptosis,
Free Radic. Biol. Med. 48 (2010) 749–762.
[51] Y. Zhang, O. Marcillat, C. Giulivi, L. Ernster, K.J. Davies, The oxidative inactivation
of mitochondrial electron transport chain components and ATPase, J. Biol. Chem.
265 (1990) 16330–16336.
[52] E. Hervouet, A. Cizkova, J. Demont, A. Vojtiskova, P. Pecina, N.L. Franssen-van Hal, J.
Keijer, H. Simonnet, R. Ivanek, S. Kmoch, C. Godinot, J. Houstek, HIF and reactive
oxygen species regulate oxidative phosphorylation in cancer, Carcinogenesis 29
(2008) 1528–1537.
[53] M.P. Murphy, How mitochondria produce reactive oxygen species, Biochem. J.
417 (2009) 1–13.
[54] K.B. Choksi, J.E. Nuss, W.H. Boylston, J.P. Rabek, J. Papaconstantinou, Age-related
increases in oxidatively damaged proteins of mouse kidney mitochondrial
electron transport chain complexes, Free Radic. Biol. Med. 43 (2007) 1423–1438.
[55] K.B. Choksi, J.E. Nuss, J.H. Deford, J. Papaconstantinou, Age-related alterations in
oxidatively damaged proteins of mouse skeletal muscle mitochondrial electron
transport chain complexes, Free Radic. Biol. Med. 45 (2008) 826–838.
[56] R. Requejo, T.R. Hurd, N.J. Costa, M.P. Murphy, Cysteine residues exposed on pro-
tein surfaces are the dominant intramitochondrial thiol and may protect against
oxidative damage, FEBS J. 277 (2010) 1465–1480.
[57] J. Trnka, F.H. Blaikie, R.A. Smith, M.P. Murphy, A mitochondria-targeted
nitroxide is reduced to its hydroxylamine by ubiquinol in mitochondria, Free
Radic. Biol. Med. 44 (2008) 1406–1419.
[58] C.L. Chen, J. Chen, S. Rawale, S. Varadharaj, P.P. Kaumaya, J.L. Zweier, Y.R. Chen,
Protein tyrosine nitration of the ﬂavin subunit is associated with oxidative mod-
iﬁcation of mitochondrial complex II in the post-ischemic myocardium, J. Biol.
Chem. 283 (2008) 27991–28003.
[59] Y.R. Chen, C.L. Chen, D.R. Pfeiffer, J.L. Zweier, Mitochondrial complex II in the
post-ischemic heart: oxidative injury and the role of protein S-glutathionylation,
J. Biol. Chem. 282 (2007) 32640–32654.
[60] J.E. Ricci, C. Munoz-Pinedo, P. Fitzgerald, B. Bailly-Maitre, G.A. Perkins, N. Yadava,
I.E. Schefﬂer, M.H. Ellisman, D.R. Green, Disruption of mitochondrial function
during apoptosis is mediated by caspase cleavage of the p75 subunit of complex
I of the electron transport chain, Cell 117 (2004) 773–786.
[61] D. Hanahan, R.A. Weinberg, The hallmarks of cancer, Cell 100 (2000) 57–70.
[62] K.B. Wallace, A.A. Starkov, Mitochondrial targetes of drug toxicity, Annu. Rev.
Pharmacol. Toxicol. 40 (2000) 353–388.
[63] P.P. Hsu, D.M. Sabatini, Cancer cell metabolism: Warburg and beyond, Cell 134
(2008) 703–707.
[64] M.G. VanderHeiden, L.C. Cantley, C.B. Thompson, Understanding theWarburg effect:
the metabolic requirements of cell proliferation, Science 324 (2009) 1029–1033.
[65] I. Samudio, M. Fiegl, M. Andreeff, Mitochondrial uncoupling and the Warburg
effect: molecular basis for the reprogramming of cancer cell metabolism, Cancer
Res. 69 (2009) 2163–2166.
[66] D. Anastasiou, G. Poulogiannis, J.M. Asara, M.B. Boxer, J.K. Jiang, M. Shen, G.
Bellinger, A.T. Sasaki, J.W. Locasale, D.S. Auld, C.J. Thomas, M.G. Vander Heiden,
L.C. Cantley, Inhibition of pyruvate kinase M2 by reactive oxygen species con-
tributes to cellular antioxidant responses, Science 334 (2011) 1278–1283.
[67] J.W. Kim, I. Tchernyshyov, G.L. Semenza, C.V. Dang, HIF-1-mediated expression
of pyruvate dehydrogenase kinase: a metabolic switch required for cellular
adaptation to hypoxia, Cell Metab. 3 (2006) 177–185.
[68] I. Papandreou, R.A. Cairns, L. Fontana, A.L. Lim, N.C. Denko, HIF-1 mediates adap-
tation to hypoxia by actively downregulating mitochondrial oxygen consump-
tion, Cell Metab. 3 (2006) 187–197.
[69] G.L. Semenza, B.H. Jiang, S.W. Leung, R. Passantino, J.P. Concordet, P. Maire, A.
Giallongo, Hypoxia response elements in the aldolase A, enolase 1, and lactate
dehydrogenase A gene promoters contain essential binding sites for hypoxia-
inducible factor 1, J. Biol. Chem. 271 (1996) 32529–32537.
[70] K. Guo, G. Searfoss, D. Krolikowski, M. Pagnoni, C. Franks, K. Clark, K.T. Yu, M.
Jaye, Y. Ivashchenko, Hypoxia induces the expression of the pro-apoptotic
gene BNIP3, Cell Death Differ. 8 (2001) 367–376.
[71] S. Rikka, M.N. Quinsay, R.L. Thomas, D.A. Kubli, X. Zhang, A.N. Murphy, A.B.
Gustafsson, Bnip3 impairs mitochondrial bioenergetics and stimulates mito-
chondrial turnover, Cell Death Differ. 18 (2011) 721–731.
[72] Z. Chen, Y. Li, H. Zhang, P. Huang, R. Luthra, Hypoxia-regulated microRNA-210
modulates mitochondrial function and decreases ISCU and COX10 expression,
Oncogene 29 (2010) 4362–4368.
[73] A.M. Cervera, N. Apostolova, F.L. Crespo, M. Mata, K.J. McCreath, Cells silenced
for SDHB expression display characteristic features of the tumor phenotype,
Cancer Res. 68 (2008) 4058–4067.
[74] P.L. Dahia, K.N. Ross, M.E. Wright, C.Y. Hayashida, S. Santagata, M. Barontini, A.L.
Kung, G. Sanso, J.F. Powers, A.S. Tischler, R. Hodin, S. Heitritter, F. Moore, R.
Dluhy, J.A. Sosa, I.T. Ocal, D.E. Benn, D.J. Marsh, B.G. Robinson, K. Schneider, J.
Garber, S.M. Arum, M. Korbonits, A. Grossman, P. Pigny, S.P. Toledo, V. Nose, C.
Li, C.D. Stiles, A HIF1alpha regulatory loop links hypoxia and mitochondrial
signals in pheochromocytomas, PLoS Genet. 1 (2005) 72–80.
[75] B.E. Baysal, Clinical and molecular progress in hereditary paraganglioma, J. Med.
Genet. 45 (2008) 689–694.
[76] L. Amar, J. Bertherat, E. Baudin, C. Ajzenberg, B. Bressac-de Paillerets, O. Chabre,
B. Chamontin, B. Delemer, S. Giraud, A. Murat, P. Niccoli-Sire, S. Richard, V.Rohmer, J.L. Sadoul, L. Strompf, M. Schlumberger, X. Bertagna, P.F. Plouin, X.
Jeunemaitre, A.P. Gimenez-Roqueplo, Genetic testing in pheochromocytoma or
functional paraganglioma, J. Clin. Oncol. 23 (2005) 8812–8818.
[77] N. Burnichon, V. Rohmer, L. Amar, P. Herman, S. Leboulleux, V. Darrouzet, P.
Niccoli, D. Gaillard, G. Chabrier, F. Chabolle, I. Coupier, P. Thieblot, P. Lecomte,
J. Bertherat, N. Wion-Barbot, A. Murat, A. Venisse, P.F. Plouin, X. Jeunemaitre,
A.P. Gimenez-Roqueplo, The succinate dehydrogenase genetic testing in a
large prospective series of patients with paragangliomas, J. Clin. Endocrinol.
Metab. 94 (2009) 2817–2827.
[78] R.G. Feichtinger, F.A. Zimmermann, J.A. Mayr, D. Neureiter, M. Ratschek, N. Jones,
W. Sperl, B. Koﬂer, Alterations of respiratory chain complexes in sporadic
pheochromocytoma, Front. Biosci. (Elite Ed.) 3 (2011) 194–200.
[79] J. Waldmann, P. Langer, N. Habbe, V. Fendrich, A. Ramaswamy, M. Rothmund,
D.K. Bartsch, E.P. Slater, Mutations and polymorphisms in the SDHB, SDHD,
VHL, and RET genes in sporadic and familial pheochromocytomas, Endocrine
35 (2009) 347–355.
[80] L. Amar, E. Baudin, N. Burnichon, S. Peyrard, S. Silvera, J. Bertherat, X. Bertagna, M.
Schlumberger, X. Jeunemaitre, A.P. Gimenez-Roqueplo, P.F. Plouin, Succinate dehy-
drogenase B genemutations predict survival in patients withmalignant pheochro-
mocytomas or paragangliomas, J. Clin. Endocrinol. Metab. 92 (2007) 3822–3828.
[81] C.C. Boedeker, H.P. Neumann,W.Maier, B. Bausch, J. Schipper,G.J. Ridder,Malignant
head and neck paragangliomas in SDHB mutation carriers, Otolaryngol. Head Neck
Surg. 137 (2007) 126–129.
[82] A.P. Gimenez-Roqueplo, N. Burnichon, L. Amar, J. Favier, X. Jeunemaitre, P.F.
Plouin, Recent advances in the genetics of phaeochromocytoma and functional
paraganglioma, Clin. Exp. Pharmacol. Physiol. 35 (2008) 376–379.
[83] H.P. Neumann, C. Pawlu, M. Peczkowska, B. Bausch, S.R. McWhinney, M.Muresan, M.
Buchta, G. Franke, J. Klisch, T.A. Bley, S. Hoegerle, C.C. Boedeker, G. Opocher, J.
Schipper, A. Januszewicz, C. Eng, Distinct clinical features of paraganglioma syn-
dromes associatedwith SDHB and SDHDgenemutations, JAMA292 (2004) 943–951.
[84] C. Ricketts, E.R. Woodward, P. Killick, M.R. Morris, D. Astuti, F. Latif, E.R. Maher,
Germline SDHB mutations and familial renal cell carcinoma, J. Natl. Cancer Inst.
100 (2008) 1260–1262.
[85] R.N. Schimke, D.L. Collins, C.A. Stolle, Paraganglioma, neuroblastoma, and a
SDHB mutation: resolution of a 30-year-old mystery, Am. J. Med. Genet. A
152A (2010) 1531–1535.
[86] S.R. McWhinney, B. Pasini, C.A. Stratakis, Familial gastrointestinal stromal
tumors and germ-line mutations, N. Engl. J. Med. 357 (2007) 1054–1056.
[87] K.A. Janeway, S.Y. Kim, M. Lodish, V. Nose, P. Rustin, J. Gaal, P.L. Dahia, B. Liegl,
E.R. Ball, M. Raygada, A.H. Lai, L. Kelly, J.L. Hornick, M. O'Sullivan, R.R. de
Krijger, W.N. Dinjens, G.D. Demetri, C.R. Antonescu, J.A. Fletcher, L. Helman,
C.A. Stratakis, Defects in succinate dehydrogenase in gastrointestinal stromal
tumors lacking KIT and PDGFRA mutations, Proc. Natl. Acad. Sci. U. S. A. 108
(2011) 314–318.
[88] J.P. Bayley, P. Devilee, P.E. Taschner, The SDH mutation database: an online
resource for succinate dehydrogenase sequence variants involved in pheochro-
mocytoma, paraganglioma and mitochondrial complex II deﬁciency, BMC Med.
Genet. 6 (2005) 39.
[89] N. Burnichon, J.J. Briere, R. Libe, L. Vescovo, J. Riviere, F. Tissier, E. Jouanno, X.
Jeunemaitre, P. Benit, A. Tzagoloff, P. Rustin, J. Bertherat, J. Favier, A.P.
Gimenez-Roqueplo, SDHA is a tumor suppressor gene causing paraganglioma,
Hum. Mol. Genet. 19 (2010) 3011–3020.
[90] A.P. Gimenez-Roqueplo, J. Favier, P. Rustin, C. Rieubland, M. Crespin, V. Nau, P.
Khau Van Kien, P. Corvol, P.F. Plouin, X. Jeunemaitre, Mutations in the SDHB
gene are associated with extra-adrenal and/or malignant phaeochromocytomas,
Cancer Res. 63 (2003) 5615–5621.
[91] F.H. van Nederveen, J. Gaal, J. Favier, E. Korpershoek, R.A. Oldenburg, E.M. de Bruyn,
H.F. Sleddens, P. Derkx, J. Riviere, H. Dannenberg, B.J. Petri, P. Komminoth, K. Pacak,
W.C. Hop, P.J. Pollard, M. Mannelli, J.P. Bayley, A. Perren, S. Niemann, A.A.
Verhofstad, A.P. de Bruine, E.R. Maher, F. Tissier, T. Meatchi, C. Badoual, J. Bertherat,
L. Amar, D. Alataki, E. Van Marck, F. Ferrau, J. Francois, W.W. de Herder, M.P.
Peeters, A. van Linge, J.W. Lenders, A.P. Gimenez-Roqueplo, R.R. de Krijger, W.N.
Dinjens, An immunohistochemical procedure to detect patientswith paraganglioma
and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a
retrospective and prospective analysis, Lancet Oncol. 10 (2009) 764–771.
[92] P.B. Douwes Dekker, P.C. Hogendoorn, N. Kuipers-Dijkshoorn, F.A. Prins, S.G. van
Duinen, P.E. Taschner, A.G. van der Mey, C.J. Cornelisse, SDHD mutations in head
and neck paragangliomas result in destabilization of complex II in the mitochon-
drial respiratory chain with loss of enzymatic activity and abnormal mitochon-
drial morphology, J. Pathol. 201 (2003) 480–486.
[93] A.P. Gimenez-Roqueplo, J. Favier, P. Rustin, J.J. Mourad, P.F. Plouin, P. Corvol, A.
Rotig, X. Jeunemaitre, The R22X mutation of the SDHD gene in hereditary
paraganglioma abolishes the enzymatic activity of complex II in the mitochon-
drial respiratory chain and activates the hypoxia pathway, Am. J. Hum. Genet.
69 (2001) 1186–1197.
[94] H.X. Hao, O. Khalimonchuk, M. Schraders, N. Dephoure, J.P. Bayley, H. Kunst, P.
Devilee, C.W. Cremers, J.D. Schiffman, B.G. Bentz, S.P. Gygi, D.R. Winge, H.
Kremer, J. Rutter, SDH5, a gene required forﬂavination of succinate dehydrogenase,
is mutated in paraganglioma, Science 325 (2009) 1139–1142.
[95] A. Blank, A.M. Schmitt, E. Korpershoek, F. van Nederveen, T. Rudolph, N. Weber,
R.T. Strebel, R. de Krijger, P. Komminoth, A. Perren, SDHB loss predicts malignancy
in pheochromocytomas/sympathethic paragangliomas, but not through hypoxia
signalling, Endocr. Relat. Cancer 17 (2010) 919–928.
[96] W. Habano, T. Sugai, S. Nakamura, N. Uesugi, T. Higuchi, M. Terashima, S.
Horiuchi, Reduced expression and loss of heterozygosity of the SDHD gene in
colorectal and gastric cancer, Oncol. Rep. 10 (2003) 1375–1380.
572 S. Grimm / Biochimica et Biophysica Acta 1827 (2013) 565–572[97] L. Putignani, S. Raffa, R. Pescosolido, L. Aimati, F. Signore, M.R. Torrisi, P.
Grammatico, Alteration of expression levels of the oxidative phosphorylation
system (OXPHOS) in breast cancer cell mitochondria, Breast Cancer Res. Treat.
110 (2008) 439–452.
[98] D. Ghezzi, P. Goffrini, G. Uziel, R. Horvath, T. Klopstock, H. Lochmuller, P. D'Adamo,
P. Gasparini, T.M. Strom, H. Prokisch, F. Invernizzi, I. Ferrero, M. Zeviani, SDHAF1,
encoding a LYR complex-II speciﬁc assembly factor, is mutated in SDH-defective
infantile leukoencephalopathy, Nat. Genet. 41 (2009) 654–656.
[99] J.P. Bayley, H.P. Kunst, A. Cascon, M.L. Sampietro, J. Gaal, E. Korpershoek, A.
Hinojar-Gutierrez, H.J. Timmers, L.H. Hoefsloot, M.A. Hermsen, C. Suarez, A.K.
Hussain, A.H. Vriends, F.J. Hes, J.C. Jansen, C.M. Tops, E.P. Corssmit, P. de Knijff,
J.W. Lenders, C.W. Cremers, P. Devilee, W.N. Dinjens, R.R. de Krijger, M.
Robledo, SDHAF2 mutations in familial and sporadic paraganglioma and
phaeochromocytoma, Lancet Oncol. 11 (2010) 366–372.
[100] E. Dibrov, S. Fu, B.D. Lemire, The Saccharomyces cerevisiae TCM62 gene encodes a
chaperone necessary for the assembly of the mitochondrial succinate dehydro-
genase (complex II), J. Biol. Chem. 273 (1998) 32042–32048.
[101] M.G. Vander Heiden, J.S. Choy, D.J. VanderWeele, J.L. Brace, M.H. Harris, D.E.
Bauer, B. Prange, S.J. Kron, C.B. Thompson, C.M. Rudin, Bcl-x(L) complements
Saccharomyces cerevisiae genes that facilitate the switch from glycolytic to
oxidative metabolism, J. Biol. Chem. 277 (2002) 44870–44876.
[102] C. Klanner, W. Neupert, T. Langer, The chaperonin-related protein Tcm62p
ensures mitochondrial gene expression under heat stress, FEBS Lett. 470 (2000)
365–369.[103] L.G. Nijtmans, S.M. Artal, L.A. Grivell, P.J. Coates, The mitochondrial PHB complex:
roles inmitochondrial respiratory complex assembly, ageing and degenerative dis-
ease, Cell. Mol. Life Sci. 59 (2002) 143–155.
[104] L.G. Nijtmans, L. de Jong, M. Artal Sanz, P.J. Coates, J.A. Berden, J.W. Back, A.O.
Muijsers, H. van der Spek, L.A. Grivell, Prohibitins act as a membrane-bound
chaperone for the stabilization of mitochondrial proteins, EMBO J. 19 (2000)
2444–2451.
[105] C.T. Schwall, V.L. Greenwood, N.N. Alder, The stability and activity of respiratory
complex II is cardiolipin-dependent, Biochim. Biophys. Acta 1817 (2012)
1588–1596.
[106] M. Crimi, M.D. Esposti, Apoptosis-induced changes in mitochondrial lipids,
Biochim. Biophys. Acta 1813 (2011) 551–557.
[107] F. Gonzalvez, Z.T. Schug, R.H. Houtkooper, E.D. MacKenzie, D.G. Brooks, R.J.
Wanders, P.X. Petit, F.M. Vaz, E. Gottlieb, Cardiolipin provides an essential acti-
vating platform for caspase-8 on mitochondria, J. Cell Biol. 183 (2008) 681–696.
[108] J. Neuzil, J.C. Dyason, R. Freeman, L.F. Dong, L. Prochazka, X.F. Wang, I. Schefﬂer,
S.J. Ralph, Mitocans as anti-cancer agents targeting mitochondria: lessons from
studies with vitamin E analogues, inhibitors of complex II, J. Bioenerg.
Biomembr. 39 (2007) 65–72.
[109] L.F. Dong, P. Low, J.C. Dyason, X.F. Wang, L. Prochazka, P.K. Witting, R. Freeman,
E. Swettenham, K. Valis, J. Liu, R. Zobalova, J. Turanek, D.R. Spitz, F.E. Domann, I.E.
Schefﬂer, S.J. Ralph, J. Neuzil, Alpha-tocopheryl succinate induces apoptosis by
targeting ubiquinone-binding sites in mitochondrial respiratory complex II,
Oncogene 27 (2008) 4324–4335.
